Research
Hormonal
Weight loss reduces circulating levels of pro-inflammatory adipokines (leptin, TNF-α, IL-6) and improves endothelial function, thereby mitigating oxidative stress and cardiovascular risk.
Losing weight directly reduces the inflammatory burden on your body. This improves blood vessel health and reduces the risk of heart disease and diabetes. Focus on sustainable weight reduction to lower these biological risks.
ModerateSupportsHIGH confidence
When there is weight loss, circulating levels of the hormone [leptin] are reduced, and in turn, these levels reduce the plasma levels of obesity-associated inflammatory markers... weight loss improves endothelium-dependent vasodilatation, improves endothelial activation markers, and decreases proinflammatory cytokine levels.
Why this rating
Based on review of multiple studies cited in the text.
Source
Inflammation, Oxidative Stress, and Obesity
Alba Fernández-Sánchez et al. · International Journal of Molecular Sciences · 2011
DOI 10.3390/ijms12053117
narrative_reviewCited 1,508×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity induces systemic oxidative stress and chronic low-grade inflammation through adipose tissue dysfunction, specifically via increased adipokine secretion (leptin, TNF-α, IL-6) and mitochondrial ROS production, which leads to endothelial dysfunction and insulin resistance.Moderate
- Dietary patterns high in fat and carbohydrates exacerbate oxidative stress and inflammation in obese individuals, while antioxidant intake (e.g., fruit) may mitigate lipid peroxidation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →